Lung Cancer

Lung Cancer

Melissa Johnson, MD

SCRI, is coauthor on the Late Breaking Abstract, “Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial,” that will be presented during the Plenary Session on Sunday, May 31 at 2:13 p.m. CDT in Hall B1.  

Click here to learn more about Dr. Johnson.